# Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

> **NCT05751668** · PHASE2 · SUSPENDED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 98 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Chemotherapy-Induced Peripheral Neuropathy
- Metastatic Breast Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Monosialotetrahexosylganglioside
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-life assessment
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT05751668
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-11-02
- **Primary completion:** 2028-03-15
- **Final completion:** 2032-03-15
- **Target enrollment:** 98 (ESTIMATED)
- **Why stopped:** Interim analysis
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751668, "Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05751668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*